LYELL IMMUNOPHARMA INC. - COMMON STOCK

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

01 May 2025 08:00:08 By Nasdaq GlobeNewswire

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

15 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

11 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

18 Feb 2025 15:05:00 By Nasdaq GlobeNewswire

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

09 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

09 Dec 2024 20:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

07 Nov 2024 15:05:03 By Nasdaq GlobeNewswire

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

31 Oct 2024 15:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

24 Oct 2024 15:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

04 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

24 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in September Investor Conferences

28 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

07 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

26 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

03 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

07 May 2024 15:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

06 May 2024 07:00:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

28 Feb 2024 15:05:00 By Nasdaq GlobeNewswire